Podcast: Managing the Allergic Flare: Clinical Strategies & Novel Options With Dr. Griffin
Joya Griffin, DVM, DACVD
Sponsored by Elanco
When an allergic flare strikes, fast and effective relief is critical—not just for patient comfort but to prevent chronic skin damage and infection as well. In this podcast episode, dermatology specialist Dr. Joya Griffin dives into how to diagnose the source of pruritus, how to choose between starting symptomatic treatment or performing additional diagnostics, and how to integrate Janus kinase (JAK) inhibitors into the multimodal management of allergic disease in dogs.
Contact us:
Podcast@instinct.vet
Where to find us:
Website:
YouTube:
Facebook:
LinkedIn:
X:
Instagram:
The Team:
Beth Molleson, DVM - Host
Sarah Pate - Producer & Project Manager, Brief Studio
Taylor Argo - Podcast Production & Sound Editing
INDICATIONS
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Read the entire package insert before using this drug, including the Boxed Warning. For full prescribing information call 1-888-545-5973 or visit http://www.elancolabels.com/us/zenrelia WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.
Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-25-1479
